PersonExecutiveOperator
Andrea Ashford-Hicks
Andrea Ashford-Hicks is the CEO of Cayuga Biotech, an early-stage platform biotechnology company developing biomimetic polyphosphate therapies for severe bleeding. She joined in 2022 after two decades in biopharma, including leading the FDA approval and commercial launch of RETHYMIC at Enzyvant Therapeutics and progressive roles at Johnson & Johnson, Pfizer, Agenus, EMD Serono and Schering-Plough. She holds dual degrees in biology and finance from the University of Pennsylvania and the Wharton School.
andrea ashford-hickscayuga biotechceobiotechnologybiopharma executivedrug development